Cencora (COR) Stock Price, News & Analysis

+0.26 (+0.11%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
920,108 shs
Average Volume
1.27 million shs
Market Capitalization
$47.47 billion
P/E Ratio
Dividend Yield
Price Target

Cencora MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
8.3% Downside
$218.22 Price Target
Short Interest
4.70% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.19mentions of Cencora in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.01 B Sold Last Quarter
Proj. Earnings Growth
From $13.43 to $14.64 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.94 out of 5 stars

Medical Sector

192nd out of 909 stocks

Drugs, Proprietaries, & Sundries Industry

5th out of 6 stocks

COR stock logo

About Cencora Stock (NYSE:COR)

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

COR Stock Price History

COR Stock News Headlines

At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
Cencora (COR) to Release Quarterly Earnings on Wednesday
Cencora, Inc. (COR)
At first glance, this chart looks like nonsense…
We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”
Cencora, Inc.: Raising target to $270
Cencora (COR) Reported a Strong Q4 and Rose 14%
Are Medical Stocks Lagging Artivion (AORT) This Year?
See More Headlines
Receive COR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 2/26 Dividend
Dividend Payable
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Drugs, proprietaries, & sundries
Health Care Distributors
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
$1.75 billion
Pretax Margin


Sales & Book Value

Annual Sales
$262.17 billion
Cash Flow
$17.17 per share
Book Value
$3.32 per share


Free Float
Market Cap
$47.45 billion

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Should I Buy Cencora Stock? COR Pros and Cons Explained


Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Cencora, Inc. has received a "Moderate Buy" recommendation from analysts, indicating positive sentiment towards the company's performance.
  • The average 1-year price target for Cencora, Inc. is $214.90, suggesting potential for growth in the stock price.
  • Recent insider activity includes major shareholder Walgreens Boots Alliance, Inc. selling shares at a higher price, indicating confidence in the company's future prospects.
  • Cencora, Inc. offers a diverse range of healthcare solutions and services, catering to various segments of the healthcare industry, which can lead to stable revenue streams.
  • The company's international presence in distributing pharmaceuticals and healthcare products provides opportunities for global expansion and revenue diversification.


Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • Despite positive analyst ratings, there are concerns about potential market volatility affecting the stock price of Cencora, Inc.
  • Recent insider selling activities, such as EVP Elizabeth S. Campbell selling shares, may raise questions about the company's internal outlook.
  • Competition in the healthcare distribution industry is intense, which could impact Cencora, Inc.'s market share and profitability.
  • Regulatory changes in the pharmaceutical sector could pose challenges to Cencora, Inc.'s operations and financial performance.
  • Investors should carefully monitor the company's financial reports and industry trends to assess the long-term sustainability of Cencora, Inc.'s business model.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

COR Stock Analysis - Frequently Asked Questions

Should I buy or sell Cencora stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.
View COR analyst ratings
or view top-rated stocks.

What is Cencora's stock price target for 2024?

8 brokerages have issued 1 year price targets for Cencora's stock. Their COR share price targets range from $182.00 to $261.00. On average, they predict the company's share price to reach $218.22 in the next twelve months. This suggests that the stock has a possible downside of 8.3%.
View analysts price targets for COR
or view top-rated stocks among Wall Street analysts.

How have COR shares performed in 2024?

Cencora's stock was trading at $205.38 at the beginning of the year. Since then, COR shares have increased by 15.9% and is now trading at $237.95.
View the best growth stocks for 2024 here

When is Cencora's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our COR earnings forecast

How can I listen to Cencora's earnings call?

Cencora will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "702498".

How were Cencora's earnings last quarter?

Cencora, Inc. (NYSE:COR) issued its earnings results on Wednesday, January, 31st. The company reported $3.28 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.42. The company earned $72.25 billion during the quarter, compared to the consensus estimate of $68.81 billion. Cencora had a net margin of 0.69% and a trailing twelve-month return on equity of 323.23%. During the same period last year, the business posted $2.71 earnings per share.

How often does Cencora pay dividends? What is the dividend yield for Cencora?

Cencora declared a quarterly dividend on Wednesday, January 31st. Stockholders of record on Friday, February 9th will be paid a dividend of $0.51 per share on Monday, February 26th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, February 8th. This is a boost from the stock's previous quarterly dividend of $0.24.
Read our dividend analysis for COR

Is Cencora a good dividend stock?

Cencora (NYSE:COR) pays an annual dividend of $2.04 per share and currently has a dividend yield of 0.86%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 22.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, COR will have a dividend payout ratio of 13.93% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for COR.

What guidance has Cencora issued on next quarter's earnings?

Cencora issued an update on its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of 13.250-13.500 for the period, compared to the consensus estimate of 13.450. The company issued revenue guidance of $288.4 billion-$293.6 billion, compared to the consensus revenue estimate of $291.9 billion.

What is Paul E. Szurek's approval rating as Cencora's CEO?

27 employees have rated Cencora Chief Executive Officer Paul E. Szurek on Glassdoor.com. Paul E. Szurek has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Cencora own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cencora investors own include Digital Realty Trust (DLR), NVIDIA (NVDA), Cisco Systems (CSCO), AbbVie (ABBV), Crown Castle (CCI), AT&T (T), Intel (INTC), Realty Income (O), QUALCOMM (QCOM) and Enterprise Products Partners (EPD).

Who are Cencora's major shareholders?

Cencora's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.49%), Wealth Enhancement Advisory Services LLC (0.14%), Raymond James & Associates (0.14%), Allspring Global Investments Holdings LLC (0.10%), Cookson Peirce & Co. Inc. (0.10%) and Los Angeles Capital Management LLC (0.09%). Insiders that own company stock include Elizabeth S Campbell, Gina Clark, Gina Clark, John G Chou, John G Chou, Lazarus Krikorian, Leslie E Donato, Leslie E Donato, Robert P Mauch, Robert P Mauch, Silvana Battaglia, Steven H Collis and Walgreens Boots Alliance, Inc.
View institutional ownership trends

How do I buy shares of Cencora?

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Cencora have any subsidiaries?
The following companies are subsidiares of Cencora: AB Singapore Investments Pte Ltd, AB UK Holdings Ltd, ASD Specialty Healthcare LLC, Access M.D., Alliance Healthcare, Amerisource Receivables Financial Corporation, AmerisourceBergen Drug Corporation, AmerisourceBergen Global Holdings GmbH, AmerisourceBergen Global Manufacturer Services GmbH, AmerisourceBergen Group GmbH, AmerisourceBergen International Holdings Inc., AmerisourceBergen Luxembourg S.a.r.L., AmerisourceBergen Services Corporation, AmerisourceBergen Sourcing LLC, AmerisourceBergen Specialty Group LLC, Anderson Packaging, AutoMed Technologies, BPL Group LLC, BPLH Ireland Unlimited Company, Bellco Health, Brecon Pharmaceuticals, Bridge Medical Inc, CD Smith Healthcare, H. D. Smith, IgG America, International Physician Networks L.L.C., IntrinsiQ, Lash Group, MWI Veterinary Supply, Network for Medical Communications & Research, PMSI, PharMEDium Healthcare, Pharmacy Healthcare Solutions, Premier Source, St. Francis Group, Trent Drug, US Bioservices, Wight Nederland Holdco 2 BV, World Courier, World Courier Group S.à r.l., and Xcenda.
Read More
This page (NYSE:COR) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners